Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec appointment
confidence 75%
filed 2026-09-08
Aatish V Patel ceased serving as President of XCHG Limited and was appointed General Manager of the Company's wholly-owned U.S. subsidiary, XCharge Energy USA Inc., effective September 7, 2026. While this involves both a departure from one role and an appointment to another, the filing emphasizes the appointment to the subsidiary leadership position as the principal action, framed as a strategic reassignment to strengthen U.S. operations. The amendment to his offer letter and the material nature of a President-level executive's repositioning make this material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-08
Item 2.02
The filing discloses enGene's financial results for the three and nine months ended July 31, 2026, including operating expenses ($34.0 million for Q3 2026), net loss ($32.5 million or $0.47 per share), and cash position ($266.3 million). The press release attached as Exhibit 99.1 is a standard earnings announcement with financial metrics and operational updates, filed under Item 2.02 (Results of Operations and Financial Condition), which is the canonical Item for earnings releases.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Thomas Civik was appointed as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, transitioning from his interim role since February 2026. The appointment includes compensatory arrangements (stock option grant and sign-on bonus), severance terms, and related governance changes including John Flavin's transition to Lead Independent Director and Dr. Palani's resignation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 7.01
IonQ announced updated full-year 2026 financial guidance ($450–$460 million revenue) following its July 31, 2026 acquisition of SkyWater Technology. While the guidance itself resembles an earnings-release disclosure, the core event is the post-acquisition integration and combined operational outlook. The filing emphasizes "executing on a shared roadmap" and "immediate financial and operational strength of bringing IonQ and SkyWater together," signaling a strategic operational milestone rather than a routine earnings announcement. The guidance is material to investors assessing the combined entity's trajectory, but the primary disclosure centers on the operational and strategic implications of the completed M&A integration rather than quarterly/annual results alone.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-08
Item 2.02
Group 1 Automotive announced a $1.25 billion offering of senior unsecured notes ($625 million due 2032 and $625 million due 2035) in a private placement to fund the Hennessy Acquisition and related expenses, including repayment of revolving credit facility borrowings.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 72%
filed 2026-09-08
Item 8.01
Strategy Inc disclosed material capital allocation activities including an increase in its Digital Credit Securities Repurchase Program authorization from $1.0 billion to $2.0 billion, repurchases of preferred stock totaling $176.3 million, and maintenance of a USD Reserve intended to support dividend payments on preferred stock.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
The disclosure announces FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder, following positive Phase 3 Emerge study results showing statistically significant efficacy (8.1-point placebo-adjusted MADRS improvement, p<0.0001). This is a material regulatory milestone that accelerates development and review of an innovative medicine for a serious condition with significant unmet need, but does not fit the specific operational categories (workforce reduction, material contract, partnership, product milestone). The event is clearly operational/strategic—a regulatory achievement that advances the company's lead program—rather than financial, governance, legal, or existential in nature.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
Glenn Boehnlein was appointed to the Board of Directors effective September 4, 2026, bringing significant financial and medical-technology sector expertise. Concurrently, Board Chair Boon Hwee Koh retired on the same date, and Dow R. Wilson was elected as the new Board chair.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-08
Item 8.01
The filing discloses two material debt-related transactions: (1) entry into a new $5.0 billion revolving credit agreement on September 4, 2026, replacing the existing facility and increasing available capacity, and (2) a pending Three-Year Delayed Draw Term Loan Agreement for up to $2.0 billion to finance the CIRCOR Acquisition. While the CIRCOR Acquisition itself is the underlying strategic event, the 8-K Item 8.01 disclosure centers on the creation of new direct financial obligations and credit facilities to support that acquisition, making debt_issuance the most precise classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Veru announced a strategic shift in its drug development pipeline: advancing sabizabulin into Phase 2b clinical trials for daraxonrasib-resistant metastatic pancreatic cancer based on new positive preclinical data, while discontinuing exploration of sabizabulin for atherosclerotic cardiovascular disease. This represents a material operational and strategic decision affecting the company's pipeline priorities and resource allocation, but does not fit the specific categories of M&A, impairment, litigation, or other defined event types. The decision is material to investors as it redirects development efforts toward a potentially significant oncology indication with unmet medical need.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-08
Item 1.01
Eagle Financial Services Inc. entered into a definitive merger agreement with John Marshall Bancorp, Inc. on September 7, 2026, whereby EFSI shareholders will receive 2.00 shares of JMSB common stock per EFSI share, creating a combined entity with approximately $4.4 billion in pro forma assets and positioning the combined company as the 5th largest bank headquartered in Virginia.
View raw filing on EDGAR →
6-K
Earnings release
confidence 25%
filed 2026-09-08
EX-99.1
This exhibit is a clinical trial data presentation for CHAPTER-3 Phase 3 study of deucrictibant XR for long-term prophylaxis of hereditary angioedema (HAE). While it discloses positive topline results (83% attack rate reduction vs. placebo, p<0.0001, all secondary endpoints met, well-tolerated safety profile), it is not a financial earnings release but rather a clinical/scientific presentation of investigational drug trial outcomes. The document explicitly states "This presentation includes data for an investigational product not yet approved by regulatory authorities" and focuses on efficacy, safety, and quality-of-life endpoints rather than financial results. However, for a clinical-stage biopharmaceutical company, positive Phase 3 data is material to investors' assessment of the company's prospects and regulatory pathway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-09-08
Item 2.02
Fidelity Core Real Estate Fund disclosed Q2 2026 quarterly financial results, including a net total return of 1.66%, annualized since-inception return of 9.02%, gross portfolio value of $671.4M, investor equity of $404.3M, and a quarterly dividend of $0.1361/share.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board appointed Benjamin Graboske as a Class III director effective immediately, with a term expiring at the 2027 Annual Meeting. This is a clear director appointment disclosed under Item 5.02. While the section also mentions director compensation arrangements, the principal disclosed action is the appointment itself, not a compensation modification. The appointment is material as it expands the Board from six to seven members and affects governance structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
ASP Isotopes disclosed its inaugural Capital Markets Day event in London on September 8, 2026, where management outlined strategy across multiple business segments (nuclear medicine, electronics, helium/LNG, nuclear fuels) and provided operational updates on commercialization progress, including expected revenue growth from liquid helium production and stable isotope shipments, plus a long-term EBITDA target of $300 million by 2031. This is a strategic business communication disclosing material operational milestones and forward guidance, but does not fit the specific categories of earnings release, M&A, debt issuance, or other defined event types—making it an operational disclosure of strategic importance to investors.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-08
Item 8.01
QNB Corp. executed a strategic repositioning of its available-for-sale securities portfolio, selling $254.4 million in securities at a weighted-average yield of 1.59% and purchasing higher-yielding securities at 5.45%. The Company estimates a net pre-tax loss of $26.2 million on the sale, which will be included in Q3 2026 results. This is a material financial event involving a significant portfolio restructuring and realized loss, but does not fit the specific categories of debt issuance, dividend distribution, material impairment, or restatement—making it a financial event that is clearly material but not categorized by a named type.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-09-08
EX-99.1
This is an announcement of an upcoming earnings call and financial results disclosure for Q1 fiscal year 2027. While the actual financial results are not yet disclosed in this exhibit (they will be issued "prior to the call" on September 14, 2026), the exhibit is a formal announcement of the earnings event itself, which is a material disclosure that would affect investor assessment of the company's periodic financial performance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
HarbourVest Private Equity Secondaries Fund sold 189,000 unregistered Class I limited partnership units for $1.9 million on August 3, 2026, to accredited investors and qualified purchasers as part of a continuous private offering exempt from registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-08
Item 3.02
HarbourVest Private Equity Secondaries Fund L.P. sold 250,017 unregistered Class I limited partnership units for $2.98 million on August 3, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
The filing discloses multiple unregistered private placements of equity securities totaling approximately $2.87 million across Class A-I, Class A-II, and Class E common stock issued to accredited investors and independent directors pursuant to Section 4(a)(2) and Regulation D Rule 506(c). These are classic dilutive issuances that increase share count and dilute existing shareholders, with the largest tranches (Class A-II shares totaling ~$2.86 million) issued to accredited investors in private placements exempt from registration.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-08
EX-99.1
SNDL Inc. is holding an annual and special meeting of shareholders on October 15, 2026, to address multiple governance matters including receipt of audited financial statements, election of five directors, re-appointment of auditor CBIZ CPAs P.C., and approval of a special resolution for share consolidation on a basis of 1-for-2 to 1-for-10. The proposed share consolidation represents a material capital structure change requiring shareholder approval.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-08
Item 7.01
The filing discloses the declaration of monthly distributions by Cantor Fitzgerald Income Trust across multiple share classes and operating partnership units, with specific per-unit amounts (ranging from $0.086460 to $0.086503) representing 5.00% of NAV on an annual basis. The distributions are payable to holders of record as of August 31, 2026, and will be paid on or about September 8, 2026, either in cash or reinvested through the company's distribution reinvestment plan. This is a routine but material disclosure of dividend/distribution activity for a closed-end fund.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-08
Item 5.02
Gillian B. Zucker informed the board on September 3, 2026 that she does not intend to stand for reelection to the board when her term expires at the 2026 Annual Meeting. This is a director departure — the principal disclosed action is a board member leaving office. The filing explicitly states the decision was not due to disagreement with the Company, indicating a routine non-reelection rather than a contested departure, but it remains a material change in board composition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-09-08
Item 5.02
Bruce W. Harting's retirement from the Board of Directors of Financial Institutions, Inc. and its subsidiary Five Star Bank, effective immediately on September 1, 2026, constitutes a departure of a director. While the filing also describes Susan R. Holliday's technical resignation and reappointment for reclassification purposes (which is administrative and does not represent a true departure), the material event disclosed is Harting's board departure. The filing explicitly states his decision was to pursue outside interests and did not result from disagreement, but the departure itself is the principal disclosed action requiring classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Intellia announced FDA acceptance of a Biologics License Application (BLA) with Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a PDUFA target date of March 10, 2027. This represents a material regulatory milestone in the drug development and commercialization pathway for the company's lead product candidate.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-08
Item 5.02
Ajit Mohan, Chief Business Officer of Snap Inc., notified the company on September 3, 2026 that he will depart, with his last day expected to be December 31, 2026. This is a clear executive departure of a principal officer. The departure of a C-suite executive responsible for business operations is material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Xponential Fitness appointed Jennifer Ryu as Chief Financial Officer, effective October 19, 2026, succeeding interim CFO Robert Julian. The appointment includes a base salary of $550,000, target bonus of 60%, sign-on bonus of $150,000, and equity grants valued at $1.7 million.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-09-08
Item 5.02
The filing discloses adoption of Form RSU Documents and grants of restricted stock units to three named executives: Eric Williams (EVP of Engineering, 750,000 RSUs), Rahul Shukla (CFO, 500,000 RSUs), and Kenneth Canavan (COO, 500,000 RSUs), each vesting over approximately four years. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from executive departures or appointments. The aggregate equity value and multi-year vesting schedules make this material to investors assessing executive compensation and capital allocation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-08
Item 1.01
Blue Owl Capital Corporation completed a $398 million term debt securitization transaction on September 2, 2026, involving the issuance of $267 million in secured notes (Class A-1, A-F, B, and C notes) and $25 million in Class A-L loans under a credit agreement, all backed by a portfolio of middle market loans.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-08
Item 8.01
The registrant implemented a 1-for-3 reverse stock split on September 4, 2026, approved by the Board of Trustees. While a reverse stock split is a capital structure event, it is primarily a governance/administrative action affecting share structure rather than a material financial, operational, or existential event. The split does not change the total value of shareholders' investments or portfolio holdings, and the monthly distribution was proportionally adjusted to maintain cash flow. This is a governance matter that would affect investor perception of the fund's trading profile and liquidity, warranting materiality classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
BridgeBio disclosed new clinical trial data for its lead oncology programs (BBO-8520, BBO-11818, BBO-10203) and announced a strategic portfolio prioritization, deprioritizing certain programs (BBO-8520 in 1L NSCLC and BBO-10203 in breast cancer) while focusing capital on higher-probability opportunities. This is a material operational and strategic business event—the company is reallocating resources based on clinical progress and competitive landscape—but does not fit the specific categories of earnings release, M&A, impairment, or other named types. The disclosure includes encouraging efficacy data (75% ORR for BBO-8520 + pembrolizumab) and cash runway into 2028, both relevant to investor assessment of the company's prospects.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-08
Item 8.01
The filing discloses a Board declaration of a quarterly cash dividend of $0.17 per share, payable October 13, 2026, to shareholders of record as of September 30, 2026. This is a routine but material dividend distribution that affects shareholder value and is customarily disclosed via 8-K Item 8.01.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-08
Item 5.02
Sunita Holzer, Chief Human Relations Officer, is retiring from her role at Verisk Analytics. The disclosure centers on her departure—a named executive officer leaving the company—rather than on a replacement appointment or compensation arrangement. The retirement is material as it involves a C-suite executive departure affecting organizational leadership.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-09-08
Item 8.01
The disclosure describes a material cybersecurity incident in which an unauthorized party obtained vendor credentials to access a Company API and downloaded personal data of patients, including Social Security numbers. Although the Company states it does not believe the incident is "reasonably likely to have a material impact" on business or financial condition, the incident itself—involving unauthorized access to sensitive personal data and triggering law enforcement notification, customer notification, credit monitoring, and ongoing investigation—constitutes a material cybersecurity incident under Item 1.05 (required disclosure since 2023). The compromise of customer personal data and the Company's prompt incident response protocols confirm this is a reportable cybersecurity event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-08
Item 5.02
Kevin Thornal, Group President of Global Businesses and the Americas, is departing the company effective September 30, 2026, following a position restructuring. Thornal will receive severance benefits under the Executive Severance Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-08
Item 7.01
Three executives were promoted effective October 1, 2026: Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data. All three will report directly to the CEO as part of a leadership restructuring designed to streamline operations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-08
Item 2.01
Solaris Energy Infrastructure completed the acquisition of Omega Foundation Services on September 1, 2026, for approximately $101 million in net cash consideration, $28 million in debt and lease assumption, and issuance of 3.6 million Class A shares. The acquisition expands the company's EPC capabilities and is expected to be immediately accretive to earnings and free cash flow per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-08
Item 3.02
As part of the Omega Foundation Services acquisition, Solaris Energy Infrastructure issued approximately 3.6 million Class A shares as consideration, completed under Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
The filing discloses an unregistered sale of 1,067,178 common shares for approximately $22.29 million under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement of equity securities exempt from registration, which is material to investors as it increases share count and dilutes existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
Goldman Sachs Real Estate Finance Trust Inc sold 189,583 Class I shares and 147,694 Class S shares in a private offering for approximately $8.46 million, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 8.01
The Company declared monthly distributions to shareholders across six classes of common stock and originated four new mortgage loans totaling approximately $233.9 million, including Self-Storage 5-Pack ($39.8M), Fort Worth Industrial ($26.5M), Dallas Office ($123.2M), and Atlanta Multifamily ($44.5M).
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-08
Item 2.01
AEVEX completed the acquisition of Maritime Applied Physics, LLC (BlackSea Technologies) on September 8, 2026, for $600 million enterprise value comprising 12.7 million shares of Class A common stock ($350 million) plus cash and up to $50 million in contingent consideration. The transaction combines two scaled defense providers to create a multi-domain autonomous systems company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-08
Item 8.01
DCG International Investments Ltd. acquired approximately $100 million in shares of the Zcash ETF through an Authorized Participant in exchange for 85,705.32563297 ZEC tokens. This represents a significant capital raise for the fund and constitutes an issuance of new shares to a major investor (an affiliate of the fund's sponsor). While the shares have no preference features and are economically identical to other shares, the transaction is material to investors as it represents substantial new capital inflow and potential dilution to existing shareholders, particularly given that DCG is an affiliate of the sponsor.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 1.01
Amylyx entered into manufacturing and supply agreements with Bachem (definitive) and Polypeptide (term sheet) to secure long-term supply of avexitide drug substance for commercial use. While Item 1.01 typically covers M&A activity, these are strategic operational/supply agreements essential to the company's ability to commercialize its lead drug candidate, not acquisitions or dispositions. The agreements establish minimum purchase commitments beginning in 2028 and include a $30 million upfront fee to Polypeptide, making this a material operational milestone for a biopharmaceutical company dependent on third-party manufacturing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-08
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 "Results of Operations and Financial Condition." The press release announces quarterly financial results including revenue, operating expenses, net income, and cash position, with the full text furnished as Exhibit 99.1. The disclosure is material as it reports significant financial performance including a $125.9 million net income swing and $172.8 million in cash, alongside material corporate developments (FDA NDA acceptance, IPO completion for $220.8 million gross proceeds).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-08
Item 1.01
Worthington Steel's subsidiary entered into a Domination and Profit and Loss Transfer Agreement (DPLTA) with Kloeckner & Co SE following completion of a voluntary public takeover offer on June 3, 2026 and Kloeckner's delisting from the Frankfurt Stock Exchange on August 12, 2026. The DPLTA grants Worthington Steel GmbH binding control over Kloeckner's management and profits/losses, with effectiveness expected on January 1, 2027, subject to Kloeckner shareholder approval at an October 23, 2026 meeting.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-08
Item 8.01
This Item 8.01 disclosure reports material progress on a previously announced merger: Repligen's acquisition of BioLife Solutions for $11.25 cash and 0.1442 shares per share. The filing confirms that the HSR antitrust waiting period expired on September 3, 2026, removing a key closing condition, and notes that BioLife stockholder approval is scheduled for October 5, 2026. This is a material acquisition activity update that would significantly affect investor assessment of Repligen's strategic direction and capital deployment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-08
Item 1.01
Chime Financial entered into a definitive Merger Agreement on September 8, 2026, to acquire Stride Bank (via Central Service Corporation) for $590 million in cash. The transaction, expected to close in H1 2027, is subject to regulatory approvals from the Federal Reserve and OCC, and will transform Chime from a fintech partner into a bank holding company with direct ownership of banking infrastructure and expected synergies exceeding $100 million.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-08
The 6-K announces implementation of a shareholder-approved share consolidation (1-for-30 ratio) effective September 17, 2026 on Nasdaq Capital Market. While share consolidations are governance/capital structure events rather than discrete material events in the traditional 8-K taxonomy, this disclosure is material to investors as it affects share count, trading mechanics, and potential delisting risk mitigation. The announcement supersedes a prior announcement of a 1-for-40 ratio, indicating a change in the Board's determination of the consolidation ratio within shareholder-approved parameters.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-09-08
EX-99.1
The press release announces the ex-dividend date and payment details for BW LPG's Q2 2026 cash dividend: NOK 8.8914 per share (or US$0.95 per share). This is a routine but material dividend distribution to shareholders, disclosed in connection with the ex-dividend trading date on both the Oslo and New York Stock Exchanges.
View raw filing on EDGAR →